-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Reasons to buy the ‘HER2-Positive Breast Cancer Epidemiology’ market report: Get an overview of the HER2+ breast cancer risk factors, comorbidities, and global and historical epidemiological trends in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). Get valuable insights into the 10-year epidemiology forecast for Diagnosed incident cases of all invasive breast cancer Diagnosed incident cases of HER2+ breast cancer Five diagnosed prevalent cases of HER2+ breast cancer Understand the diagnosed incident cases...
-
Thematic Analysis
Digital Therapeutics – Thematic Intelligence
Explore actionable trends and insights with the following data sets in the ‘Digital Therapeutics’ report: Market analysis of approved and reimbursed digital therapeutic products by region. Case studies with in-depth insight into some of the most recent and most influential developments in the digital therapeutics theme. Product profiles of disruptive digital therapeutic products across key therapeutic areas. A focused chapter on the key healthcare, technology, macroeconomic, and regulatory trends impacting digital therapeutics, and a review of how these trends will...
-
Product Insights
Digital Health Market Size, Share and Trends Analysis by Region, Product, Technology (Telemedicine, mHealth, Digital Therapeutics, Others), Therapy Area (Dermatology, Rheumatology, Gastroenterology) and Segment Forecast, 2022-2027
The digital health in immunology market size was valued at US$6.07 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 24.2% during 2022-2027. Digital health has a broad scope and includes the use of wearable devices, mobile health, telehealth, health information technology, and telemedicine. Digital health applications in immunology have gained significant momentum owing to the following factors: Enhanced access to healthcare Affordable cost of healthcare Improve the quality of care Reduce any...
-
Report Bundle
50% offInnovations in Pharma – Report Bundle (5 Reports)
Innovations in Pharma Bundle Report Overview The healthcare industry constantly demands innovation, improvement, accessibility, and affordability. The ‘Innovations in Pharma’ bundle highlights the emerging drug development technologies in providing quality healthcare services. Accessing the in-depth insight from the Innovations in Pharma bundle can help you: Make informed decisions about investments, partnerships, and product development Understand your competitors’ strengths and weaknesses, identify areas of opportunity, and develop strategies to stay ahead in the market Anticipate market changes and adjust your strategies accordingly...
-
Report Bundle
56% offTech in Healthcare – Report Bundle (7 Reports)
Technologies such as AI, cloud, VR, AR, and IoT have multiple applications in the healthcare sector. It helps to design tools and software to boost hospital and administrative productivity. The COVID-19 pandemic has prompted the implementation and development of devices such as wearables at a much faster rate. As a part of this bundle, you will gain access to in-depth insights available in the following reports: Thematic Research: AI in Healthcare Thematic Research: Cloud Computing in Healthcare Thematic Research: Coordinated...
-
Report Bundle
37% offTech in Medical – Report Bundle (5 Reports)
The medical field can learn new things about therapies, data collection, symptom and illness research, cure research, and human helping gadgets by applying technology (like hearing devices and speaking devices). The medical field is now highly accessible to individuals because of technology. As a part of this bundle, you will gain access to in-depth insights available in the following reports: Thematic Research: Augmented Reality in Healthcare Thematic Research: Internet of Things in Healthcare Thematic Research: Robotics in Medical Thematic Research:...
-
Report Bundle
26% offTrends in Pharma – Report Bundle (4 Reports)
‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for...
-
Sector Analysis
Chronic Kidney Disease Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Chronic Kidney Disease Market Report Overview The chronic kidney disease (CKD) market size was valued at $1.3 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 17% during the forecast period. Chronic kidney disease, or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a...
-
Sector Analysis
Systemic Sclerosis – Global Drug Forecast and Market Analysis to 2030
Systemic sclerosis (SSc) is a rare, multisystem autoimmune disease that causes progressive fibrosis of the skin and internal organs, as well as vascular dysfunction. The presentation of the disease is heterogeneous, both in the organ systems affected and the overall severity of symptoms. The most common complications of SSc include digital vasculopathy (Raynaud’s phenomenon and digital ulcers), skin fibrosis, lung fibrosis or interstitial lung disease (ILD), pulmonary arterial hypertension, gastrointestinal issues, arthritis, myopathy, and scleroderma renal crisis. As there are...
-
Sector Analysis
Malignant Mesothelioma – Competitive Landscape in 2021
In malignant mesothelioma, cells expressing mesothelin is a major focus of drug developers. There are 178 drugs in the pipeline with 84% molecules present in early stage development. Big Pharma dominates R&D in this indication, with Bayer and Eli Lilly leading the way. The rise in treatment receiving population and increasing preference for branded tbiologic herapies will drive the market's growth over the next six years, but delayed diagnosis and low surveillance rate are likely to limit market growth.